NCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
Clinical Trials
37 trialsNCT05114746 2026-04-01
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
NCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06216249 2026-03-10
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06004661 2026-03-06
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Novartis
Phase 2 Recruiting
NCT05670106 2026-02-13
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
Novartis
Phase 2 Active not recruiting
NCT05176223 2026-02-05
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Mayo Clinic
Phase 2 Completed
NCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT04777071 2026-01-09
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
Phase 2 Active not recruiting
NCT04176497 2025-12-11
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT04762888 2025-10-31
68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
Mayo Clinic
Phase 2 Completed
NCT06521775 2025-09-12
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma
Mayo Clinic
Phase 2 Completed
NCT06200103 2025-09-11
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06067269 2025-07-15
HEATWAVE
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT06560905 2025-07-01
PPPIMS
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT04716725 2024-10-16
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Active not recruiting
NCT06484361 2024-07-03
PET/MRI to Stage Prostate Cancer Patients
IRCCS San Raffaele
Phase 2 Recruiting
NCT03762759 2024-05-17
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University
Phase 2 Active not recruiting
NCT04243941 2024-03-21
PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT05034562 2024-03-07
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04264208 2024-02-01
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Stanford University
Phase 2 Terminated
NCT03809078 2024-01-11
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Stanford University
Phase 2 Completed
NCT03396874 2023-11-03
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
University of Michigan
Phase 2 Completed
NCT04483414 2023-05-19
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT05806853 2023-04-10
PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study
IRCCS San Raffaele
Phase 2 Completed
NCT04179968 2023-03-20
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT04928820 2022-10-21
68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT03689582 2022-01-05
Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT04050215 2021-09-30
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT03463889 2021-06-29
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02611882 2020-12-22
PSMA PET
University of California, San Francisco
Phase 2 Completed
NCT03515577 2020-10-14
PSMA vs AXUMIN
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT03675451 2020-10-14
PSMA Imaging of Localized Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Completed
NCT02282137 2020-08-19
PSMA
Radio Isotope Therapy of America
Phase 2 Unknown
NCT03207139 2019-07-17
Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer
Chang Gung Memorial Hospital
Phase 2 Completed
NCT02796807 2018-03-06
Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Completed
NCT02810886 2017-08-22
ProsPERo
Jules Bordet Institute
Phase 2 Withdrawn